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Abstract
Plasmodium falciparum infection can abruptly progress to severe malaria, a life-threatening complication resulting from
sequestration of parasitized red blood cells (PRBC) in the microvasculature of various organs such as the brain and lungs.
PRBC adhesion can induce endothelial cell (EC) activation and apoptosis, thereby disrupting the blood-brain barrier.
Moreover, hemozoin, the malarial pigment, induces the erythroid precursor apoptosis. Despite the current efficiency of
antimalarial drugs in killing parasites, severe malaria still causes up to one million deaths every year. A new strategy
targeting both parasite elimination and EC protection is urgently needed in the field. Recently, a rho-kinase inhibitior
Fasudil, a drug already in clinical use in humans for cardio- and neuro-vascular diseases, was successfully tested on
laboratory strains of P. falciparum to protect and to reverse damages of the endothelium. We therefore assessed herein
whether Fasudil would have a similar efficiency on P. falciparum taken directly from malaria patients using contact and non-
contact experiments. Seven (23.3%) of 30 PRBC preparations from different patients were apoptogenic, four (13.3%) acting
by cytoadherence and three (10%) via soluble factors. None of the apoptogenic PRBC preparations used both mechanisms
indicating a possible mutual exclusion of signal transduction ligand. Three PRBC preparations (42.9%) induced EC apoptosis
by cytoadherence after 4 h of coculture (‘‘rapid transducers’’), and four (57.1%) after a minimum of 24 h (‘‘slow
transducers’’). The intensity of apoptosis increased with time. Interestingly, Fasudil inhibited EC apoptosis mediated both by
cell-cell contact and by soluble factors but did not affect PRBC cytoadherence. Fasudil was found to be able to prevent
endothelium apoptosis from all the P. falciparum isolates tested. Our data provide evidence of the strong anti-apoptogenic
effect of Fasudil and show that endothelial cell-P. falciparum interactions are more complicated than previously thought.
These findings may warrant clinical trials of Fasudil in severe malaria management.
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Introduction
Plasmodium falciparum malaria remains a major life-threatening
parasitic disease, killing about a million people each year, mainly
in sub-Saharan Africa [1,2,3,4]. Young children and pregnant
women are particularly vulnerable. Why some non immune
individuals die whereas others have uncomplicated or even
asymptomatic infection is not known [5].
P. falciparum initially infects the liver before undergoing
intrerythrocytic development through an asexual replication cycle
[6]. This infection can progress unpredictably to severe forms,
notably including anemia and cerebral malaria (CM) [7].
CM accounts for a significant proportion of the morbidity and
mortality associated with malaria in children less than five years.
Despite a massive amount of experimental and clinical work, the
pathophysiologic mechanisms of this complication are poorly
understood, although several studies implicate sequestration of
P. falciparum-parasitized red blood cells (PRBC) within the
brain [8,9,10,11,12]. This sequestration is characterized by
PRBC adhesion (or cytoadherence), agglutination and rosetting
[13,10,14]. Cytoadherence of PRBC to host endothelial cells
(EC) in brain and lung capillaries can obstruct the microvascu-
lature, a phenomenon accompanied by changes in the T cell
repertoire and by cytokine production [15]. This cytoadherence
is mediated by EC receptors such as CD36, intracellular
adhesion molecule 1 (ICAM1), vascular cellular adhesion
molecule 1 (VCAM1), CD31, integrins, thrombospondin, E-
selectin and chondroitin sufate A [16,17], PRBC adhesion can
induce over-expression of inflammatory cytokines [15,18],
coagulation factors [19] and EC apoptosis [20,21]. Blood-brain
barrier (BBB) impairment associated with a direct cytotoxic effect
of PRBC on EC has also been observed [22,23]. It has been
postulated that PRBC-mediated EC apoptosis could amplify
BBB dysfunction [20]. More recently it has been demonstrated
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13221that hemozoin, the malarial pigment induces the erythroid
precursor apoptosis [24].
Human lung endothelial cells (HLEC) are widely used to study
the pathophysiology of P. falciparum malaria in vitro [25]. Using
HLEC/PRBC coculture, we have previously shown that EC
apoptosis triggered by cytoadherence may lead to neurological
complications in P. falciparum malaria; however, only some P.
falciparum isolates induced EC apoptosis [26]. We have also
identified new PRBC ligands (Plasmodium apoptosis–linked
pathogenicity factors, PALPF) associated with parasite apopto-
genicity [27]. Although most of these PALPF are transmembrane
proteins, only some are involved in parasite cytoadherence.
Parasite elimination is more beneficial in controlling the
pathology. Host response to the infection is critical for CM
development. However, the presence of the parasite is not
harmless during a CM case, when in fact, it likely triggers the
host response that promotes disease. Conventional emergency
treatment is based on intravenous administration of antimalarial
drugs such as quinine and artemisinin derivatives [28]. Despite
effective parasite clearance, up to 20% of patients die and others
have permanent sequelae [29,30]. A new strategy combining
parasite eradication and EC protection is therefore needed.
Rho kinase (ROCK), a serine threonine-specific protein kinase,
is activated when it binds to GTP and is inactivated when it binds
to GDP. Rho kinase phosphorylates many substrate proteins [31]
and plays a key role in EC signal transduction through receptors
such as ICAM1, VCAM1 and selectins [32]. Rho kinases are
involved in PRBC–EC interactions: PRBC adhesion to EC
activates the Rho kinase pathway, leading to EC apoptosis [33].
Fasudil (HA-1077) is a Rho kinase inhibitor that attenuates NF-
kappa B activation [34]. Fasudil has been marketed since 1995 in
Japan for the treatment of ischemic stroke [35]. Recently, it was
shown that EC apoptosis can be inhibited by Fasudil [34], but
these results were obtained only with in vitro-adapted parasite
strains, although one of which was isolated from a CM patient.
There are no relevant data on field isolates.
Here we examined the effect of fasudil on EC apoptosis
mediated by RBC infected by field isolates. Two approaches were
used: 1) contact coculture, to measure apoptosis mediated by
cytoadherence; and 2) non contact experiments to examine the
role of diffusible stimuli. We then examined the effect of fasudil on
both mechanisms of EC apoptosis.
Results
Patients
Three hundred symptomatic children aged from 1 to 14 years
were recruited for the study. Fifty-four children (18%) were found
to be infected with P. falciparum. There were 53 cases of
uncomplicated malaria and one case of severe malaria (hyperpar-
asitemia: 26%) in the WHO classification.
Parasites
Parasitemia ranged from 0.3% to 26% (table 1 and 2). Thirty of
the 54 isolates were selected for further study. After enrichment
using Plasmagel or gelatin flotation, PRBC specimens were found
to be almost exclusively at the schizont stage and parasitemia was
between 4% and 55% (data not shown).
Table 1. Plasmodium falciparum parasitized red blood cells (PRBC)-mediated human lung endothelial cells (HLEC) apoptosis
induction and inhibition by Fasudil: Seventeen PRBC from F747 to F625 were cocultured in contact conditions (cytoadherence).
Pf isolates Para.(%) Nb* Schiz. (x10
6) Cyto. Per 1000 HLEC Apoptosis induction/inhibition (OD)
4 hours 24 hours
Fasudil2 Fasudil+ Fasudil2 Fasudil+
F747 1.3 8 29 0.36 0.29 1.7 1.2
F463 1 - 199 32
F464 3 - 3 2.23 0.61 2.5 2
F803 3.2 - 29 3.1 1.67 18 4.8
F856 0.3 - 10 0.82 0.81 1.10 0.9
F862 1.5 - 12 1.21 1.17 2.15 1.
F949 3.4 - 3 1.01 0.85
F126 2- 7 9 4.71 1.56 28.27 7.4
F528 1.3 - 202 0.83 0.62 1.5 1.2
F969 4 - 200 1.28 0.72 1.49 0.91
F995 3.5 - 2 0.86 0.43 1.54 0.73
F2008 2 - 4 0.98 0.89 2 1.8
F127** 26 - 0.79 0.58 4.12 1.78
F593 3 - 200 0.27 0.17 0.7 0.68
F609 2 - 150 0.49 0.33 0.5 0.16
F619 5 - 50 0.35 0.24 2.1 0.4
F625 4 - 100 0.5 0.28 1.69 1.69
Para., parasitemia; Nb, number; schiz. Schizont;
*(8610
6); Cyto., cytoadherence; OD., optical density. In red colour OD values of apoptosis positive and inhibition by Fasudil.
**Hyperparasitemia (Severe malaria case).
doi:10.1371/journal.pone.0013221.t001
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The number of schizonts in each PRBC preparation used in the
cytoadherence tests was estimated at 24610
6. Binding assays were
carried out with 17 PRBC samples. The adhesion was determined
for 16 PRBC with values ranging from 2 to 202 PRBC per 1000
HLEC (Table 1). The number of adherent uninfected red blood
cells was negligible. Fasudil had no effect on the PRBC adherence
(data not shown).
Apoptosis
The number of schizonts in each PRBC sample used in
apoptosis assays was approximately 8610
6 and 200610
6 per well
respectively for contact and non contact experiments.
Contact coculture. Thirty PRBC samples were each tested
in quadruplicate for their capacity to induce HLEC apoptosis via
cytoadherence. Four PRBC samples (13.1%) were found to trigger
HLEC apoptosis in these conditions (Table 1, Figure 1). In three
cases (samples F463, F803 and F126), EC apoptosis occurred
within 4 h of coincubation, with OD ratios ranging from 3.0 to 4.7
(mean 3.6).The OD ratios for F803- and F126-activated HLEC
were 18 and 28.27 respectively (mean 23.1) after 24 h of coculture
(Table 1). With F127-activated HLEC, apoptosis was observed
after at least 24 h of coincubation, with an OD ratio of 4.12. The
mean OD ratio for F803-, F126- and F127-activated HLEC after
24 h of coculture was 16.8. These results show that apoptosis
increases significantly with time (P,0.05).
Non contact coculture. To determine whether PRBC could
induce HLEC apoptosis via the release of diffusible soluble stimuli,
without cell-cell contact, the same 30 PRBC specimens were
coincubated with HLEC in Transwells. No HLEC apoptosis was
observed after 4 h of coculture, but three specimens (10%)
(samples F528, F969 and F995) induced HLEC apoptosis after
24 h, with respective OD ratios of 3.35, 3.57 and 3.15 (mean 3.36)
(Table 2, Figure 2).
Effect of Fasudil on PRBC-mediated HLEC apoptosis
HLEC were concomitantly exposed to PRBC suspensions
containing 30 mM Fasudil in contact (96-well plates) (Table 1,
Figure 1) and non contact (Transwell) conditions (Table 2,
Figure 2) for 4 h and 24 h.
After 4 h in contact conditions, Fasudil inhibited F463-, F803-
and F126-activated HLEC apoptosis (OD), relative to untreated
controls, from 3.0 to 2.0 (34%); 3.1 to 1.67 (46.2%); and 4.7 to 1.5
(67%) respectively (mean inhibition 49.06%). At 24 h, F803-,
F126- and F127-induced HLEC apoptosis was significantly
reduced by Fasudil, from 18 to 4.8 (73.3%); 28.27 to 7.4
(73.8%) and 4.1 to 1.78 (56.8%), respectively (mean inhibition
68%).
In non contact conditions, HLEC apoptosis induced by F528,
F969 and F995 was reduced by Fasudil from 3.35 to 1.12 (66.5%);
3.57 to 1.08 (69.7%) and 3.1 to 1.0 (67.6%), respectively (mean
inhibition 68%).
Overall, 7 (23.33%) apoptogenic PRBC preparations were
identified, 4 (13.3%) requiring cytoadherence (Table 2, Figure 1)
and 3 (10%) capable of acting via soluble factors (Table 2,
Figure 2). Fasudil thus significantly reduced P. falciparum-mediated
HLEC apoptosis, by an average of 68% after 24 h, in both contact
and non contact conditions.
Discussion
Knowledge of the pathophysiological mechanisms of severe
malaria, and especially parasite ligands and host cell receptors, is
crucial for designing specific pathway inhibitors. We have
previously investigated signal transduction pathways involved in
the pathogenicity of P. falciparum malaria by using a coculture
model, and identified parasite factors linked to endothelial cell
apoptosis termed Plasmodium apoptosis-linked pathogenicitty fac-
tors (PALPF) [27]. In 2008, Taouficq et al. demonstrated that Rho
kinase inhibition by Fasudil reduced HLEC apoptosis induced by
P. falciparum.
Here we examined the effect of fasudil on PRBC-mediated
HLEC apoptosis, using P. falciparum isolates from symptomatic
patients, in contact and non contact conditions. PRBC-mediated
HLEC apoptosis has previously been studied by means of
transmission electron microscopy, annexin V assay, caspase
activity assay and nucleosome release ELISA [20].
Table 2. Plasmodium falciparum parasitized red blood cells (PRBC)-mediated human lung endothelial cells (HLEC) apoptosis
induction and inhibition by Fasudil: Ten PRBC from F528 to F625 were cocultured in non contact experiments.
Pf isolates Para. (%) Nb* schiz. (x10
6) Apoptosis induction/inhibition (OD)
4 hours 24 hours
Fasudil2 Fasudil+ Fasudil2 Fasudil+
F528 1.3 200 0.52 0.61 3.35 1.12
F2008 2 - 0.82 0.4 1.16 0.92
F126 2 0.55 0.29 0.56 0.52
F127** 26 - 0.66 0.51 0.79 0.58
F969 4 - 0.93 0.70 3.57 1.08
F593 3 - 0.98 0.39 0.8 0.74
F995 3.5 - 0.74 0.65 3.15 1.02
F609 2 - 0.66 0.61 0.5 0.3
F619 5 - 1.03 1.02
F625 4 - 1.03 1.03
Pf, Plasmodium falciparum; Para., parasitemia; Nb, number; schiz. Schizont;
*(24610
6); Cyto., cytoadherence; OD, optical density. In red colour OD values of apoptosis positive and inhibition by Fasudil.
**Hyperparasitemia (Severe malaria case).
doi:10.1371/journal.pone.0013221.t002
Fasudil and Malaria Treatment
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Figure 2. PRBC soluble factors-mediated HLEC apoptosis and inhibition by Fasudil.
doi:10.1371/journal.pone.0013221.g002
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HLEC apoptosis, 13.33% acting via cytoadherence and 10% via
parasite-derived soluble factors. We believe that field isolates have
different behaviour which remains intrinsic to the parasites and
influenced by environment (vector, host, ecology). Twenty-nine
isolates (97%) were from children with uncomplicated malaria
(Table). We have previously observed a relation between HLEC
apoptosis and severe malaria (especially neurological manifesta-
tions) and shown that HLEC apoptosis can be induced by PRBC
from patients with uncomplicated malaria [26] and even from
asymptomatic individuals (Toure ´ personal data). These previous
results suggested that uncomplicated or asymptomatic patients
harboring the apoptogenic isolates may progress more rapidly to
severe disease but the subsequent risk of developing such severe
manifestations cannot be studied in children, since for ethical
reasons treatment is started immediately after diagnosis.
Here we show, for the first time, that soluble factors released by
P. falciparum-infected erythrocytes can trigger HLEC apoptosis, in
line with the results obtained by Wilson in 2008 with human brain
endothelial cells, but conflicting with our previous observations
suggesting that direct contact between PRBC and HLEC was
required for apoptosis [20,26,33]. This discrepancy may be
explained by differences in the parasite strains and experimental
approaches used. Indeed, in our previous work, we only used
contact coculture, with PRBC isolated from symptomatic children
contrasting with Pino and Taouficq who almost exclusively used
PRBC reference strains 3D7 and F12 but in both contact and non
contact conditions.
Our results show that HLEC apoptosis triggered by PRBC
cytoadherence is detectable after only 4 h of coculture with most
apoptogenic P.falciparumstrains,andafter24 hforafurtherminority
of strains. We have already demonstrated that the capacity of PRBC
to trigger HLEC apoptosis is governed by genes encoding proteins
essential for apoptosis induction [26,27]. As the same number of
PRBCfor eachisolate was used in ourexperiments,thisdifferencein
the timing of apoptosis onset is likely due to the nature and
expression kinetics of the Plasmodium apoptosis-linked pathogenicity
factors (PALPF) involved. Wepostulate that rapid transducer ligands
(which induce EC apoptosis in 4 h) and slow transducer ligands
(which induce EC apoptosis in 24 h) may exist. If so, the nature or
affinities of HLEC receptors recognized by the two categories of
ligands are also likely to be different. In ‘‘contact’’ experiment, after
24 h coculture both stimuli (cytoadherence and soluble factors) may
be implicated in apoptosis induction. It is possible they act in
synergy. Nevertheless, our data clearly indicate that none of the
apoptogenicPRBCpreparationsusedboth mechanismssuggesting a
possible mutually exclusion of signal transduction ligand. By
contrast, in ‘‘non contact’’ only soluble factors released by parasite
coculture medium can specifically induce EC apoptosis. We also
found in contact experiments that the intensity of EC apoptosis
increased with time since the mean OD from EC apoptosis within
24 h is significantly higher than the mean OD from EC apoptosis
occurring in 4 h. Also, the apoptosis index of F803-activated HLEC
rose from 3.1 at 4 h to 18 at 24 h, i.e. by factor 5.8. This index for
F126-activated HLEC rose by a factor of 6. It is also interesting to
notice that this intensity varies between various PRBC and that
seems to be due to the level of expression of PALPF. By contrast,
HLEC apoptosis induced by soluble factors was only detected after
at least 24 h. Perhaps this delay is related to clinical threshold of the
parasite-derived stimuli released in the coculture medium.
The EC signals triggered by PRBC adhesion are unclear.
Nevertheless, PRBC adhesion modulates HLEC expression of
tumor necrosis factor-a superfamily genes (Fas, Fas L, and DR-6)
and apoptosis-related genes (Bad, Bax, caspases and iNOS etc.)
[20,21]. PRBC adhesion to EC directly activates the Rho kinase
signaling pathway and induces the production of reactive oxygen
species (ROS) by endothelial cells, both pathways potentially
leading to cell death [20,36]. Nitric oxyde (NO) overproduction
can induce cytosolic release of mitochondrial cytochrome c, which
also triggers caspase activation [37,38]. Jimenez et al. found that
binding of the CD36 ligand thrombospondin-1 was sufficient to
induce EC apoptosis mediated by p59/fyn and caspases [39].
Finally it has been suggested that CD36 and ICAM-1 are the main
EC receptors used by P. falciparum in vivo to promote parasite
survival and escape the immune system [40,41]. It is possible that
PALPF use these receptors to induce EC apoptosis. All these works
testified that the signal transduction properties from adhered
PRBC are being understood, but that triggered by PRBC-derived
soluble factors remain to be elucidated. However, it is possible that
the two stimuli have the same signaling properties. Indeed, soluble
factors or macromolecules released into the coculture medium
may be able to recognize HLEC surface receptors and induce
apoptosis via Rho kinase activation. When taken up by HLEC, the
same soluble factors may also be able to directly activate Rho
kinase. Our results also indicate that a given parasite strain induces
HLEC apoptosis either by direct contact or via soluble factors, but
not by both mechanisms. Indeed, PRBC that trigger apoptosis by
cytoadherence did not trigger the release of soluble factors capable
of inducing cell death. For example, isolate F528 was not
apoptogenic after 24 h of contact coculture (Table 1), whereas it
induced apoptosis via diffusible factors in non contact experiments
(Table 2). Ho et al. 1991 have also demonstrated the inverse
relationship between rosette formation and cytoadherence [17].
Hence P. falciparum field isolates may have a greater propensity for
cytoadherence or rosette but not both. Transcriptome analysis of
PRBC inducing HLEC apoptosis thorough cytoadherence has
revealed that pathogenicity factors (PALPF) do not act exclusively
as adhesins. Other transmembrane proteins and secretory-
excretory molecules none involved in cytoadherence have also
been identified [27], such as the trypanosome apoptogenic factor
involved in human brain EC apoptosis [42,43].
One of the most important findings of this study is that Fasudil
(HA-1077) inhibits both mechanisms leading to HLEC death
(cytoadherence and soluble factors), whereas it did not affect PRBC
cytoadherence (Table 1). Fasudil inhibits Rho kinase phosphorylation
of various substrates, including other kinases and enzymes involved in
HLEC activation [32,44,45]. This inhibition of the Rho kinase
signaling pathway may be sufficient to inhibit PRBC-mediated
HLEC apoptosis mediated both by cytoadherence and by diffusible
factors, assuming that Rhokinase is activated by both stimuli. Rho
kinase inhibition by Fasudil also inhibits NO production. Low or
physiological NO concentrations can exert an antiapoptogenic effect
on several cell types, including EC [46,47]. This antiapoptogenic
effect of NO involves several types of stimuli including TNF alpha
[48,49]. Our results reinforced the hypothesis in that preventing EC
activation could be exploited for CM treatment [50].
In conclusion, we show that the HLEC-P. falciparum interaction
is more complicated than previously thought, and points to Rho
kinase inhibition as a potential therapeutic intervention. These
findings may warrant clinical trials of fasudil in severe malaria
management.
Materials and Methods
Patients
Patients were enrolled in two local Gabonese hospitals (Centre
Hospitalier Re ´gional Amissa Bongo and Ho ˆpital de l’Amitie ´ Sino-
Gabonaise, Franceville, Haut-Ogooue ´ Province) between April
Fasudil and Malaria Treatment
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the Ethic Committee of Bio-Medical Research of Franceville
(Comite ´ d’Ethique de Recherche Bio-Me ´dicale de Franceville,
CERB) and supported by the Gabonese Ministry of Health.
Children with symptoms of acute malaria were recruited with their
parents’ or guardians’ written informed consent. World Health
Organization criteria were used to diagnose uncomplicated and
severe malaria [51]. P. falciparum was detected by thick film
(Lambare ´ne ´ method) and thin film microscopy. The children were
aged from 0 to 14 years and all had $5000 parasites/ml of blood.
Blood was drawn into sterile EDTA tubes for culture. As
compensation, all the children were treated free of charge with a
combination artesunate and amodiaquin (ArsucamH), the first-line
treatment recommended by the Gabonese authorities. Also,
biomedical analysis (blood cells account, hematocrit determination
etc.) was done freely for each child.
Plasmodium falciparum culture
Thick and thin blood films were used for diagnosis. Thick films
were prepared with Lambare ´ne ´’s method: briefly, 10 ml of total
blood was spread over a rectangle measuring 10 by 18 millimeters
on a microscope slide [52]. Parasite load was calculated as the
number of asexual forms of P. falciparum per ml of blood, as
previously reported [53].
PRBC were also selected for their ‘‘viability’’, because PRBC
from patients having self-medicated (and who rarely inform their
physician) do not grow in culture.
White cells were removed by 3 to 4 washes in RPMI 1640
incomplete culture medium. PRBC were then immediately
cultured as previously described [54]. Briefly, RPMI 1640 medium
was supplemented with 8.3 g/L HEPES, 2.1 g/L sodium
bicarbonate, 0.05 g/L hypoxanthine, 0.1 mg/mL gentamicin,
1 mg/mL fungizone, 2 g/L D-glucose and 0.4% Albumax II
(InVitrogen, Cergy Pontoise, France) and the hematocrit was
adjusted to 5%. PRBC were then incubated at 37uC for 24–48 h.
Mature PRBC were then enriched by gelatin flotation [55] and
counted under a microscope.
Culture of human lung endothelial cells (HLEC)
Ninth-passage HLEC derived from the same batch, as
documented elsewhere [33], were maintained in flasks at 37uC
with 5% CO2 in Medium 199 containing 10% (vol/vol) fetal calf
serum, 50 units/ml penicillin-streptomycin and 0.25 mg of
Fungizone (InVitrogen, Cergy Pontoise, France). Appropriate
receptor expression (von Willebrand factor, ICAM-1, VCAM-1,
CD31, CD36, E/P-selectin and CSA) was verified.
Cytoadherence assay
HLEC were resuspended in Medium 199 and subcultured at a
density of 3000 cells/well in 8-well tissue culture plates (Labtek) for
24 to 48 hours in standard conditions until confluence was reached.
Confluent HLEC were then used directly in adhesion assays, or
kept at 4uC in 300 mL of phosphate buffered saline (PBS) for a
maximum of 2 months after fixation for 20 minutes at 37uC with
2% paraformaldehyde [56]. A suspension of 300 ml of mature
PRBC (approximatively 24610
6 schizont) was added to each well
containing HLEC monolayers from Labtek in duplicate and
incubated for 1 hour at 37uC. Unbound PRBC were removed by
washing 3 times with PBS. The labtek was fixed for 20 minutes at
room temperature with 2% glutaraldehyde, rinsed with PBS and
stained with Giemsa. Adhesion was expressed as the number of
PRBC adhering to 1000 HLEC (Table 1).
Apoptosis assay
HLEC were subcultured in the lower compartment of 6-well
Transwell plates (polyester 0.4 mM pores (COSTARH, Corning
Incorporated, NY USA) and in 96-well plates (Corning Incorpo-
rated, NY USA), until confluence. A suspension of 2.500 ml
(around 200610
6) and 100 ml (around 8610
6) of each mature
PRBC preparation in parasite culture medium was added to each
well of Transwell plates and 96-well plates in duplicate and
quadruplicate, respectively, and incubated for 4 h or 24 h at 37uC.
HLEC were incubated with uninfected RBC as negative controls.
Apoptosis was measured with an enzyme linked immunosorbent
assay (ELISA) (Cell Death Detection ELISA
plus, Roche Diagnos-
tics, Mannheim, Germany).
After 4 hours of incubation in 96-well plates, PRBC and RBC
were washed 3 times with RPMI 1640 and twice with PBS. The
upper Transwell compartment containing PRBC and RBC was
removed and the supernatant was discarded. Hundred mla n d
2,500 ml of the lysis provided with the ELISA kit were used to
permeabilize HLEC in each well respectively from 96-wellplates and
Transwells, followed by 30 min of incubation at room temperature.
The plates were then centrifuged and 20 mlo fs u p e r n a t a n tp e rw e l l
was used in the ELISA. The assay measures intracytoplasmic
nucleosomes (degraded DNA) released from apoptotic HLEC.
Optical density (OD) was read using Stat FaxH 3200 (Fisher Bioblock
Scientific, Illkirch France) at 405 nm with a reference filter of
492 nm. The mean OD ratio of PRBC-activated HLEC to RBC-
activated HLEC was calculated for each PRBC preparation, using a
positivity cut-off of 3, as recommended elsewhere [20,26].
Apoptosis inhibition assay
Before contact and non contact coculture, each PRBC
suspension was treated with Fasudil at a final concentration of
30 mM.
Statistical analysis
Data were analyzed with the chi 2 test and Student’s t test. The
Mann-Whitney U test was used for non normally distributed data.
Significance was assumed at P,0.05.
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